What question did this study set out to answer?

This research aims to identify molecular mechanisms behind resistance to quizartinib in FLT3-mutated AML cells.

Quizartinib-induced resistance drives clonal emergence of MV4-11 cells with molecular alterations enabling multidrug antileukemic escape

View Full Paper

Ask AI

Bookmark

Authors

Findings reveal mechanisms of drug resistance in FLT3-ITD AML, suggesting new treatment strategies.

This research aims to identify molecular mechanisms behind resistance to quizartinib in FLT3-mutated AML cells.
Established a quizartinib-resistant FLT3-ITD AML model using MV4-11 cells.
Conducted global proteomic profiling to assess metabolic and functional changes.
Performed whole-genome sequencing to identify genetic mutations in resistant clones.
Tested the effectiveness of pharmacological agents targeting mutant p53 and MAPK signaling.
Quizartinib-resistant clones showed increased IC 50 and cytostatic responses.
Maintained MAPK signaling despite FLT3 inhibition and exhibited broad cross-resistance to multiple agents.
Acquisition of the FLT3 D835H mutation and TP53 clonal expansion indicated strong clonal selection.
Proteomic changes enhanced mitochondrial respiration and glycolysis, contributing to resistance.
Targeting mutant p53 or MAPK restored sensitivity to quizartinib, increasing apoptosis.

Miranda et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark